{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:51Z","timestamp":1791896451738,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Establishment of efficient control programs for strongyloidiasis, the infection by <jats:italic>Strongyloides stercoralis<\/jats:italic>, is among the World Health Organization (WHO) targets for 2030. Ivermectin is a drug of choice for strongyloidiasis, but its weight-based administration can be unfeasible in remote areas. We evaluated a WHO tablet pole for administration of ivermectin in school-age children living in remote villages in Ecuador.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Children were enrolled in 16 villages in Esmeraldas Province of Ecuador, between July 2021 and June 2022. The pole identified four height intervals corresponding to ivermectin doses going from one to four tablets. For each child, we calculated the dose (\u00b5g\/kg) administered with both weight-based and pole-based administration. Results were classified as follows: optimal dose, acceptable, overdose, underdose. Agreement between the two methods for estimating the number of tablets was assessed with Cohen\u2019s kappa coefficient. Estimations were reported with 95% confidence intervals (<jats:italic>CI<\/jats:italic>s).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Total of 778 children (47.3% female) were enrolled, with median age of 9.59 years (interquartile range: 7.42\u201211.22). Optimal dose was achieved for a higher proportion of children when assessed with weight (37.9%) than with pole (25.7%). Underdose and overdose were more frequent with the pole (8.3% and 19.2% children, respectively) than with the weight-based (3.7% and 6.0%, respectively) administration. Agreement between weight-based and pole-based administration was moderate: 0.56 (95% <jats:italic>CI<\/jats:italic>\u00a00.51, 0.61). The two methods indicated the same number of tablets in 71.6% (95% <jats:italic>CI<\/jats:italic>\u00a00.684, 0.748) cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our setting, the tablet pole could be a valid alternative. The tool needs further evaluation in different populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40249-023-01054-7","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:05:27Z","timestamp":1674889527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u00a0Use of a \u201ctablet pole\u201d for the administration of ivermectin for strongyloidiasis in a field study in Ecuador"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-6822","authenticated-orcid":false,"given":"Dora","family":"Buonfrate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Anselmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Prandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Montresor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"issue":"3","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1017\/S0031182016000834","volume":"144","author":"TB Nutman","year":"2017","unstructured":"Nutman TB. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology. 2017;144(3):263\u201373.","journal-title":"Parasitology"},{"issue":"6","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/pathogens9060468","volume":"9","author":"D Buonfrate","year":"2020","unstructured":"Buonfrate D, Bisanzio D, Giorli G, Odermatt P, F\u00fcrst T, Greenaway C, et al. The global prevalence of Strongyloides stercoralis infection. Pathogens. 2020;9(6):468.","journal-title":"Pathogens"},{"issue":"6","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4269\/ajtmh.18-0895","volume":"100","author":"F Tamarozzi","year":"2019","unstructured":"Tamarozzi F, Martello E, Giorli G, Fittipaldo A, Staffolani S, Montresor A, et al. Morbidity associated with chronic Strongyloides stercoralis infection: a systematic review and meta-analysis. Am J Trop Med Hyg. 2019;100(6):1305\u201311.","journal-title":"Am J Trop Med Hyg"},{"key":"1054_CR4","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health Organizaiton","year":"2020","unstructured":"World Health Organization. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. Geneva: WHO; 2020."},{"key":"1054_CR5","unstructured":"World Health Organization. Prequalification of medical products. https:\/\/extranet.who.int\/pqweb\/medicines. Accessed Sept 29 2022."},{"issue":"10","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"e0008565","DOI":"10.1371\/journal.pntd.0008565","volume":"14","author":"Y Sodahlon","year":"2020","unstructured":"Sodahlon Y, Ross DA, McPhillips-Tangum C, Lawrence J, Taylor R, McFarland DA, et al. Building country capacity to sustain NTD programs and progress: a call to action. PLoS Negl Trop Dis. 2020;14(10):e0008565.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","volume":"19","author":"D Buonfrate","year":"2019","unstructured":"Buonfrate D, Salas-Coronas J, Mu\u00f1oz J, Maruri BT, Rodari P, Castelli F, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (strong treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019;19(11):1181\u201390.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"e0008505","DOI":"10.1371\/journal.pntd.0008505","volume":"14","author":"A Montresor","year":"2020","unstructured":"Montresor A, Mupfasoni D, Mikhailov A, Mwinzi P, Lucianez A, Jamsheed M, et al. The global progress of soil-transmitted helminthiases control in 2020 and World Health Organization targets for 2030. PLoS Negl Trop Dis. 2020;14(8):e0008505.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0035-9203(01)90034-3","volume":"95","author":"A Montresor","year":"2001","unstructured":"Montresor A, Engels D, Chitsulo L, Bundy DA, Brooker S, Savioli L. Development and validation of a \u2018tablet pole\u2019 for the administration of praziquantel in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2001;95(5):542\u20134.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"e0007541","DOI":"10.1371\/journal.pntd.0007541","volume":"13","author":"CW Goss","year":"2019","unstructured":"Goss CW, O\u2019Brian K, Dubray C, Fischer PU, Hardy M, Jambulingam P, et al. Dosing pole recommendations for lymphatic filariasis elimination: a height\u2013weight quantile regression modeling approach. PLoS Negl Trop Dis. 2019;13(7):e0007541.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4269\/ajtmh.2001.65.184","volume":"65","author":"EN Shu","year":"2001","unstructured":"Shu EN, Okonkwo PO. Community-based ivermectin therapy for onchocerciasis: comparison of three methods of dose assessment. Am J Trop Med Hyg. 2001;65(3):184\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"1054_CR12","unstructured":"WHO. Preventive chemotherapy in human helminthiasis \u2013 coordinated use of anthelminthic drugs in control interventions. 2006. Available at. https:\/\/www.who.int\/publications\/i\/item\/9241547103."},{"key":"1054_CR13","unstructured":"R Core Team. R: a language and environment for statistical computing.\u00a0https:\/\/www.R-project.org\/. Accessed Sept 29\u00a02022."},{"issue":"3","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276\u201382.","journal-title":"Biochem Med"},{"issue":"10","key":"1054_CR15","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002237994","volume":"42","author":"CA Guzzo","year":"2002","unstructured":"Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122\u201333.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1054_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/dkz524","volume":"75","author":"M Navarro","year":"2020","unstructured":"Navarro M, Camprub\u00ed D, Requena-M\u00e9ndez A, Buonfrate D, Giorli G, Kamgno J, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827\u201334.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jac\/dkz083","volume":"74","author":"JD Schulz","year":"2019","unstructured":"Schulz JD, Coulibaly JT, Schindler C, Wimmersberger D, Keiser J. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2\u201312 years. J Antimicrob Chemother. 2019;74(6):1642\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1054_CR18","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S1473-3099(22)00369-3","volume":"22","author":"J Gandasegui","year":"2022","unstructured":"Gandasegui J, Onwuchekwa C, Krolewiecki AJ, Doyle SR, Pullan RL, Enbiale W, et al. Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. Lancet Infect Dis. 2022;22(11):e341\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"3\u20134","key":"1054_CR19","first-page":"361","volume":"71","author":"ND Alexander","year":"1993","unstructured":"Alexander ND, Cousens SN, Yahaya H, Abiose A, Jones BR. Ivermectin dose assessment without weighing scales. Bull World Health Organ. 1993;71(3\u20134):361\u20136.","journal-title":"Bull World Health Organ"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-023-01054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-023-01054-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-023-01054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T14:55:26Z","timestamp":1682088926000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-023-01054-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1186\/s40249-023-01054-7","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ESTRELLA study protocol received ethical clearance from the competent Ethics Committee (Comit\u00e9 de \u00c9tica de Investigaci\u00f3n en Seres Humanos de la Universidad Central del Ecuador, CEISH-UCE). Written consent was sought from the children\u2019s parents or guardians before enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}